Literature DB >> 27006272

Incidence of high dosage buprenorphine and methadone shopping behavior in a retrospective cohort of opioid-maintained patients in France.

Jessica Delorme1, Chouki Chenaf2, Jean-Luc Kabore2, Bruno Pereira3, Aurélien Mulliez3, Aurore Tremey4, Georges Brousse4, Marie Zenut5, Catherine Laporte6, Nicolas Authier7.   

Abstract

BACKGROUND: Opioid Substitution Treatment (OST) misuse and diversion have significantly increased worldwide. Obtaining OST prescriptions from multiple prescribers, known as doctor shopping, is a way in which opioids may be diverted.
OBJECTIVES: The aim of this study was to assess the incidence of OST (high dosage buprenorphine (HDB) and methadone (MTD)) shopping behavior and identify associated risk factors, and its impact on mortality.
METHODS: A retrospective cohort of patients treated by OST between April 1, 2004 and December 31, 2012 from a sample of the French Health Insurance database was established. Doctor shopping was defined as ≥1 day of overlapping prescriptions written by ≥2 different prescribers and filled in ≥3 different pharmacies.
RESULTS: A total of 2043 patients were enrolled, 1450HDB and 593 MTD. The one-year incidence of shopping behavior was 8.4% (95% CI: 7.0-10.1) in HDB group and 0% in MTD group, compared to 0.2% (95% CI: 0.1-0.2) for diuretics. On multivariate analysis, factors associated with HDB shopping behavior were: male gender HR: 1.74 (95% CI: 1.20-2.54); low-income status HR: 2.95 (95% CI: 2.07-4.44); mental health disorders HR: 1.43 (95% CI: 1.06-1.94); concurrent hypnotics use HR: 1.90 (95% CI: 1.39-2.61); concurrent use of weak opioids HR: 1.48 (95% CI: 1.09-1.99) and morphine HR: 1.69 (95% CI: 1.02-2.80). HDB shoppers had a higher, yet non-significant risk of death (HR: 1.56 (95% CI: 0.64-3.81)) than non HDB shoppers.
CONCLUSION: Shopping behavior was only found in high dosage buprenorphine patients and concerned almost one out ten patients.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Doctor shopping; High dosage buprenorphine; Methadone; Misuse; Opioid; Opioid Substitution Treatment

Mesh:

Substances:

Year:  2016        PMID: 27006272     DOI: 10.1016/j.drugalcdep.2016.02.035

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  6 in total

1.  Oral Morphine as an Alternative Substitution Treatment for Opioid Use Disorder, a Rare but Non-risk-free Use.

Authors:  Célian Bertin; Julien Bezin; Chouki Chenaf; Jessica Delorme; Nicolas Kerckhove; Antoine Pariente; Marie Tournier; Nicolas Authier
Journal:  Front Psychiatry       Date:  2022-06-30       Impact factor: 5.435

2.  Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients.

Authors:  Célian Bertin; Jessica Delorme; Marie Riquelme; Hélène Peyrière; Georges Brousse; Alain Eschalier; Denis Ardid; Chouki Chenaf; Nicolas Authier
Journal:  Br J Clin Pharmacol       Date:  2019-08-24       Impact factor: 4.335

3.  Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France.

Authors:  Perrine Roux; Daniela Rojas Castro; Khadim Ndiaye; Laélia Briand Madrid; Virginie Laporte; Marion Mora; Gwenaelle Maradan; Stéphane Morel; Bruno Spire; Patrizia Carrieri
Journal:  Subst Abuse Treat Prev Policy       Date:  2017-11-02

4.  Hazardous Drug Diversion of Valproate from a General Practitioner to his Patient's Dog.

Authors:  Pierre-Marie Morice; Joachim Alexandre; Alexandre Cesbron; Marion Sassier; Sophie Fedrizzi; Xavier Humbert
Journal:  Drug Saf Case Rep       Date:  2017-12

5.  Prevalence of Coaddictions and Rate of Successful Treatment Among a French Sample of Opioid-Dependent Patients With Long-Term Opioid Substitution Therapy: The OPAL Study.

Authors:  Marie Grall-Bronnec; Edouard-Jules Laforgue; Gaëlle Challet-Bouju; Jennyfer Cholet; Jean-Benoit Hardouin; Juliette Leboucher; Morgane Guillou-Landréat; Caroline Victorri-Vigneau
Journal:  Front Psychiatry       Date:  2019-10-17       Impact factor: 4.157

6.  Therapy without a prescription: buprenorphine/naloxone diversion and the therapeutic assemblage in Taiwan.

Authors:  Jia-Shin Chen
Journal:  Sociol Health Illn       Date:  2019-12-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.